Stockscreener 앱 받기
0.8419
6.46%
-0.0581
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Volume Recap: Is Ensysce Biosciences Inc stock dividend yield sustainableTrade Exit Report & Low Risk High Win Rate Picks - Bộ Nội Vụ
Panic Selling: Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Big Picture & Detailed Earnings Play Strategies - Bộ Nội Vụ
What sentiment indicators say about Ensysce Biosciences Inc. stockBreakout Watch & Stock Portfolio Risk Management - Улправда
Ensysce Biosciences Annual Meeting: Share Issuance Approved, PF614 Phase III and FDA Designations Update - Defense World
Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Why Ensysce Biosciences Inc. stock could be next big winnerWeekly Trade Report & AI Forecasted Stock Moves - Улправда
Ensysce Biosciences Shareholders Approve Key Corporate Actions - TipRanks
How Ensysce Biosciences Inc. stock compares to growth peersWeekly Gains Report & Safe Capital Growth Stock Tips - Улправда
How rising interest rates impact Ensysce Biosciences Inc. stockJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
Can Ensysce Biosciences Inc. stock resist market sell offsQuarterly Risk Review & Step-by-Step Trade Execution Guides - Улправда
MarketsMedicine Hat News - FinancialContent
Daily News - FinancialContent
How Ensysce Biosciences Inc. stock reacts to Fed rate cutsSell Signals and Alerts & Low Cost Trading Plans - Улправда
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - FinancialContent
ENSC: All proposals passed and clinical programs advanced, setting the stage for a pivotal year - TradingView — Track All Markets
Ensysce’s PF614 Steps Forward in Phase 3 Post-Surgery Pain Trial: What Investors Should Watch - TipRanks
Ensysce Biosciences Issues Annual Shareholder Letter - The Globe and Mail
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid By Investing.com - Investing.com India
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid - Investing.com
Inside a biotech developing pain pills with built-in overdose protection - Stock Titan
Los Angeles Daily NewsEnsysce Biosciences Issues Annual Shareholder Letter - FinancialContent
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 188.9% in December - Defense World
Will Ensysce Biosciences Inc. stock maintain growth storyWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
Why Ensysce Biosciences Inc. stock is considered a top pick2025 Trading Volume Trends & Weekly Stock Breakout Alerts - Улправда
How buybacks impact Ensysce Biosciences Inc. stock valueEarnings Performance Report & Community Shared Stock Ideas - Улправда
Can Ensysce Biosciences Inc. stock maintain operating margins2025 AllTime Highs & Verified Stock Trade Ideas - Улправда
Resistance Check: Can Ensysce Biosciences Inc. stock maintain operating marginsMarket Performance Report & High Return Trade Guides - Улправда
Ensysce Biosciences Earnings Notes - Trefis
EBIT per share of Ensysce Biosciences Inc. – OTC:ENSCW - TradingView — Track All Markets
ENSC enrolls first patient in critical phase 3 trial - MSN
Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614 - MSN
Ensysce Biosciences enrolls first patient in phase 3 pain drug trial - Investing.com Australia
Should You Buy Ensysce Biosciences After Share Sale? - StocksToTrade
Is Ensysce Biosciences a Hidden Gem? - timothysykes.com
Ensysce Biosciences enrolls first patient in phase 3 pain drug trial By Investing.com - Investing.com South Africa
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Corsicana Daily Sun
Ensysce Biosciences (NASDAQ: ENSC) starts Phase 3 PF614 trial in abuse-deterrent opioid - Stock Titan
How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan
Is Ensysce Biosciences Inc. stock near bottom after declineEarnings Beat & Weekly High Conviction Trade Ideas - Newser
Will Ensysce Biosciences Inc. stock outperform international peersProfit Target & Verified Stock Trade Ideas - Newser
Ensysce Biosciences (ENSC) Stock Analysis Report | Financials & Insights - Benzinga
Is Ensysce Biosciences, Inc. overvalued or undervalued? - Markets Mojo
Ensysce Biosciences Inc. (ENSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
4.73%
0.92%
자본화:
|
볼륨(24시간):